Policy & Compliance

  • April 15, 2026

    Aluminum Co. Settles Trans Worker's Suit Over Health Plan

    A subsidiary of Kaiser Aluminum has agreed to resolve a lawsuit claiming it discriminated against transgender employees by excluding coverage for medical treatments related to gender-affirming care from its health plan, according to a filing in Washington federal court.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 14, 2026

    4th Circ. Revives Pharma Bid To Block Maryland's 340B Law

    A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Colo. Justices Weigh Bid To Restore Trans Youth Care

    Colorado's justices pushed Children's Hospital Colorado on Tuesday to explain how its decision to halt gender-affirming care for transgender youth patients is not discriminatory, even amid the federal government's threats to cut funding for providers that offer the care to children and adolescents.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Ga. Providers Say Rutledge Bars United's Preemption Win

    Medical providers are urging a Georgia federal court to deny United's bid for an early win in its case seeking a declaration that the providers' purported attempt to claw back reimbursements for out-of-network services are preempted, arguing that state-law claims involving employee benefits aren't preempted by federal benefits law.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    Doctors Hope Justices Maintain Shield Against Med Mal Suits

    A case headed to the U.S. Supreme Court next week could roll back a legal doctrine that physicians say is key to protecting them from frivolous medical malpractice suits filed by patients who've already lost in state court.

  • April 14, 2026

    7th Circ. Suggests High Court Ruling Supports Ark. PBM Rule

    The Seventh Circuit appeared reluctant Tuesday to revive a union fund's challenge to an Arkansas rule making health plans disclose pharmacy compensation and pay fees, with judges pointing to a 2020 U.S. Supreme Court ruling that permitted state cost regulations on pharmacy benefit managers.

  • April 14, 2026

    Mich. AG Says PBMs Can't Duck Drug-Pricing Suit

    Two pharmacy benefit managers can't dodge an antitrust lawsuit accusing them of price-fixing reimbursement rates because Michigan has properly claimed an antitrust violation, state Attorney General Dana Nessel told a federal court, asking it to toss aside the PBMs' dismissal bid. 

  • April 14, 2026

    Vehicle Co. Inks $150K Deal To End Tobacco Fee Suit

    International Motors LLC, formerly Navistar, has agreed to pay $150,000 to resolve a suit claiming the company illegally charged workers an extra $600 a year if they used tobacco without giving them a proper avenue to dodge the fee, according to an Illinois federal court filing.

  • April 14, 2026

    Screening Time Deal Doesn't Bar Break Suit, Wash. Panel Says

    An eldercare company's class settlement over COVID-19 screening time doesn't bar a separate suit claiming the company failed to pay workers for missed meal breaks, a Washington state appeals court ruled, reviving the break claims.

  • April 13, 2026

    Ill. Judge Wants More Proof To Recalculate Kickback Damages

    An Illinois federal judge tasked with recalculating damages from a home health company's referral kickback scheme said Monday that she needs more complete and reliable evidence to help determine the appropriate amount, but allowed the government to continue offsetting Medicare payments as part of its judgment collection bid.

  • April 13, 2026

    Mylan Can't Revive Copaxone Antitrust Claims Against Teva

    A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.

  • April 13, 2026

    Abbott Urges Toss Of Relator, State Suits In FCA Recall Row

    Abbott Laboratories urged a Michigan federal court to throw out litigation brought by whistleblowers and a group of states over the 2022 infant formula shortage, saying their respective complaints lacked the details necessary to support claims that it defrauded numerous healthcare programs.

  • April 10, 2026

    Chest Binders Become Latest Front In Anti-Trans Litigation

    Chest binders — medical devices that can be used by individuals experiencing gender dysphoria or who want a more gender-neutral alternative to bras — have emerged as the newest target in an unfolding regulatory and legal climate that transgender advocates describe as an overtly partisan political attack against a type of product that the U.S. Food and Drug Administration has deemed the least risky.

  • April 10, 2026

    Wisconsin High Court OKs COVID Immunity For Hospitals

    A Wisconsin state appeals court erred when it held that a statute shielding healthcare providers from civil liability during the early months of the COVID-19 pandemic violated a woman's constitutional right to a jury, the state's highest court ruled unanimously Friday.

  • April 10, 2026

    Colo. Transport Co. Says Termination Lacked Due Process

    A medical transportation company that provided transportation services for Medicaid users in Denver asked a Colorado state judge to reverse a termination of its services from the state, claiming the statute used to issue the termination against the company is unconstitutional.

  • April 10, 2026

    Compass Group Workers Get Cert. For Tobacco Fee Suit

    Former employees for food service company Compass Group USA have secured class certification for their Missouri federal lawsuit claiming the company's $48 bi-weekly health insurance fee for tobacco using-workers violates federal law.

  • April 10, 2026

    Philip Morris Urges 11th Circ. To Affirm FDA Rule Toss

    Philip Morris urged the Eleventh Circuit to affirm a decision that struck down a U.S. Food and Drug Administration rule calling for graphic warnings on cigarette packaging, arguing a district court rightly found the FDA had not followed proper procedure when crafting the regulations.

  • April 10, 2026

    Drugmakers Can Intervene In Texas, Fla. Abortion Drug Suit

    A federal judge Friday allowed abortion medication manufacturers GenBioPro Inc. and Danco Laboratories to intervene in litigation brought by the states of Texas and Florida seeking to undo a slew of federal regulations concerning the abortion drug mifepristone.

  • April 10, 2026

    Elevance Can't Nix Suit Over GLP-1 Coverage For Sleep Apnea

    An Indiana federal judge declined to toss a proposed class action claiming Elevance Health Inc. illegally denied coverage for a GLP-1 weight loss medication that was prescribed to treat sleep apnea, ruling that the insurance company is the right party to answer to the allegations at play.

  • April 10, 2026

    Ill. Jury Adds $17M Punitive Award To Baby Formula Verdict

    Illinois jurors on Friday slapped another $17 million in punitive damages atop the $53 million they awarded the previous afternoon to four mothers who accused Abbott Laboratories of selling preterm infant formula that contributed to a serious and often fatal gut condition their babies developed.

  • April 09, 2026

    Yale Medical School Can't Nix Fraudulent Insemination Suit

    Yale can't escape a negligence suit by onetime patients alleging its former fertility doctor secretly inseminated them with his own sperm, after a Connecticut judge said that a letter from an anonymous doctor, which is mandated by law to support their claims, met the statutory requirements.

Expert Analysis

  • Adapting To Enforcement Focus On Wound Care Fraud

    Author Photo

    As federal agencies target wound care industry fraud as a top enforcement priority, attorneys advising industry stakeholders should evaluate business relationships for Anti-Kickback Statute violations, emphasize appropriate product use and documentation, and use internal data analytics to monitor billing patterns, say David Tarras at Tarras Defense and Jay McCormack at Verrill Dana.

  • AG Watch: Illinois A Key Player In State-Level Enforcement

    Author Photo

    Illinois Attorney General Kwame Raoul has systematically strengthened his office to fill federal enforcement gaps, oppose Trump administration mandates and advance state policy objectives, particularly by aggressively pursuing labor-related issues, say attorneys at Troutman.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

  • Federal Grantees May Soon Face More Limitations On Speech

    Author Photo

    If courts accept the administration’s new interpretation of preexisting case law, which attempts to graft onto grant recipients the existing limitations on government contractors' free speech, a more deferential standard may soon apply in determining whether an agency’s refusal or termination of a grant was in violation of the First Amendment, say attorneys at Venable.

  • HHS Wound Care Report Highlights Need For Payment Reform

    Author Photo

    The U.S. Department of Health and Human Services' recent report on potential abuse in Medicare Part B payments for skin substitutes highlights specific fraud schemes, but more importantly emphasizes that broader changes are needed for the wound care sector's fundamentally flawed payment system, say attorneys at Paul Hastings.

  • Assessing The Future Of The HIPAA Reproductive Health Rule

    Author Photo

    In light of a Texas federal court's recent decision to strike down a U.S. Department of Health and Human Services rule aimed to protect the privacy of patients seeking abortions and gender-affirming care, entities are at least temporarily relieved from compliance obligations, but tensions are likely to continue for the foreseeable future, says Liz Heddleston at Woods Rogers.

  • DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • New Health AI Guidance Features A Provider-Centric Approach

    Author Photo

    New guidance from the Joint Commission and Coalition for Health AI regarding the responsible use of artificial intelligence in healthcare deviates from preexisting guidance by recommending a comprehensive framework for using AI tools, focusing on healthcare provider organizations rather than on AI developers, say attorneys at Ropes & Gray.

  • Mass. Ruling May Pave New Avenue To Target Subpoenas

    Author Photo

    A Massachusetts federal court’s recent decision to quash a subpoena seeking information on gender-affirming care at Boston Children’s Hospital is a significant departure from courts' deferential approach to subpoena enforcement, and may open a new pathway for practitioners challenging investigative tools in the future, say attorneys at Gibson Dunn.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • How Financial Cos. Can Prep As NYDFS Cyber Changes Loom

    Author Photo

    Financial institutions supervised by the New York State Department of Financial Services can prepare for two critical cybersecurity requirements relating to multifactor authentication and asset inventories, effective Nov. 1, by conducting gap analyses and allocating resources to high-risk assets, among other steps, say attorneys at Pillsbury.

  • How Courts May Interpret Data-Driven Healthcare Fraud Suits

    Author Photo

    As the U.S. Department of Justice and other agencies increasingly turn to data mining as an enforcement tool, courts will have to determine how far data alone can take a fraud case, and sound theory, clinical expertise and institutional context will play an important role, say Jaime Jones at Sidley and Andrée-Anne Fournier and Atang Gilika at Analysis Group.

  • How Gov't Shutdown Will Affect Federal Health Agencies

    Author Photo

    Federal health agencies' contingency plans indicate that many major programs will remain insulated from disruption during the ongoing government shutdown, but significant policy proposals will likely be delayed and the Trump administration's emphasis on reduction-in-force plans distinguishes this shutdown from past lapses, says Miranda Franco at Holland & Knight.